#China #Wisconsin #Accuray #CyberKnife #Radixact

Accuray Expands Chinese Product Portfolio

Accuray Incorporated has made a significant leap in enhancing cancer treatment options in China with the recent approval from the Chinese National Medical Products Administration (NMPA) for its innovative radiation therapy systems: the Radixact SynC™ System and the CyberKnife® S7™ System. This expansion follows closely after the introduction of the Tomo® C System, marking a strategic advancement in Accuray's commitment to offering cutting-edge medical technology that meets the growing needs of Chinese healthcare providers and patients alike.

Importance of Approvals

The approval of the Radixact SynC™ and CyberKnife® S7™ Systems is pivotal. These systems provide advanced radiation therapy solutions, crucial for a country where the number of citizens requiring radiation treatment significantly exceeds current capabilities. According to estimates, approximately 2,000 radiotherapy systems will be needed over the next five years to adequately treat patients in China. Accuray's expansion into this market aims to bridge that gap and improve patient access to potentially life-saving technology.

Suzanne Winter, the president and CEO of Accuray, expressed her enthusiasm, stating, "I am thrilled with the customer adoption of the Tomo C System since its approval last year. Now with our latest CyberKnife S7 and Radixact SynC Systems, the Accuray teams in China can offer a powerful product portfolio to address clinicians' varied requirements."

Features of the Systems

Radixact SynC System

The Radixact SynC System stands out for its unique helical design, allowing for precise radiation dose delivery from multiple angles around the patient. This capability ensures that radiation conforms closely to the tumor while minimizing exposure to healthy tissues, thus enhancing treatment accuracy and safety. Notably, it is the only device in China equipped with Synchrony® real-time adaptive delivery technology, which actively tracks and adjusts the radiation beam to match the movement of tumors due to patient motion or natural bodily functions.

Additionally, the ClearRT™ imaging solution integrated with the Radixact System provides high-quality CT images, facilitating optimal patient setup and treatment monitoring, which are essential for effective tumor targeting.

CyberKnife® S7™ System

On the other hand, the CyberKnife® S7™ System represents the pinnacle of precision in radiation therapy. This robotic, non-invasive radiosurgery device treats a variety of tumors with pinpoint accuracy. Treatment sessions can be completed in just 1 to 5 outpatient visits, significantly lessening the burden on patients who might struggle with more extended treatment schedules. The S7 System's ability to deliver ultra-hypofractionated radiation therapy means higher doses can be administered in fewer sessions, streamlining patient care.

Expanding Treatment Capability

Accuray's introduction of these systems is a direct response to the pressing need for improved cancer treatment in China. With a rapidly growing population of cancer patients and an existing treatment capacity that struggles to keep pace, the availability of advanced technologies like the Radixact and CyberKnife systems is both timely and necessary. By enhancing the capabilities of local medical teams, Accuray aims to ensure that more patients can receive high-quality and efficient treatment, all while fostering better health outcomes across regions.

In summary, Accuray’s proactive strategy in deploying new radiation therapy technologies like the Radixact SynC and CyberKnife S7 highlights its dedication to improving healthcare and patient accessibility in the Asian market. As these systems launch in China, they are poised to make a significant impact on the lives of patients and the ability of clinicians to offer effective care. With its innovative spirit and commitment to quality, Accuray continues to lead the charge in the fight against cancer globally.

About Accuray

Founded with a vision of harnessing the power of radiation therapy to improve patient lives, Accuray remains at the forefront of the oncology technology landscape. With ongoing innovations and solutions spanning various complexities in treatment needs, the organization strives to empower healthcare providers with tools that can help them address the full spectrum of patient demands. Headquartered in Madison, Wisconsin, Accuray continues to expand internationally to enhance the quality of cancer care worldwide.